Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0020
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT

Nascent Biotech Company Description

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.

It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.

The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.

In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Nascent Biotech, Inc.
Nascent Biotech logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
CEOSean Carrick

Contact Details

Address:
631 US Hwy 1
North Palm Beach, Nevada 33408
United States
Phone612 961 5656
Websitenascentbiotech.com

Stock Details

Ticker SymbolNBIO
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyUSD
ISIN NumberUS63108Q1013
SIC Code2836

Key Executives

NamePosition
Sean CarrickPresident, Chief Executive Officer, Secretary and Director
Lowell HoldenChief Financial Officer, Chief Accounting Officer and Director
Dr. Mark C. Glassy Ph.D.Founder
Dr. Navpaul Singh M.D.Chief Medical Consultant